Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F K Knop

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Diabetes, Obesity & Metabolism|May 28, 2011
Glucagon antagonism as a potential therapeutic target in type 2 diabetesJ I Bagger, F K Knop, J J Holst, et al.
Diabetologia|January 17, 2007
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitusF K Knop, T Vilsbøll, S Madsbad, et al.
Diabetes, Obesity & Metabolism|November 6, 2015
Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysisU Rohde, N Hedbäck, L L Gluud, et al.
Journal of Internal Medicine|January 6, 2016
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemiaA E Junker, L Gluud, J J Holst, et al.
Diabetes, Obesity & Metabolism|July 22, 2014
Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potentialA Brønden, M Hansen, D P Sonne, et al.
Acta Diabetologica|December 14, 2011
Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutideA Faurschou, F K Knop, J P Thyssen, et al.
The Journal of Clinical Endocrinology and Metabolism|April 23, 2010
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjectsK B Hansen, T Vilsbøll, J I Bagger, et al.
Journal of Internal Medicine|July 16, 2015
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasisM Gyldenløve, T Vilsbøll, C Zachariae, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 21, 2016
Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control studyK H Mikkelsen, F K Knop, T Vilsbøll, et al.
Regulatory Peptides|June 25, 2010
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitisF K Knop, T Vilsbøll, S Larsen, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|May 28, 2011
Glucagon antagonism as a potential therapeutic target in type 2 diabetesJ I Bagger, F K Knop, J J Holst, et al.
Diabetologia|January 17, 2007
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitusF K Knop, T Vilsbøll, S Madsbad, et al.
Diabetes, Obesity & Metabolism|November 6, 2015
Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysisU Rohde, N Hedbäck, L L Gluud, et al.
Journal of Internal Medicine|January 6, 2016
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemiaA E Junker, L Gluud, J J Holst, et al.
Diabetes, Obesity & Metabolism|July 22, 2014
Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potentialA Brønden, M Hansen, D P Sonne, et al.
Acta Diabetologica|December 14, 2011
Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutideA Faurschou, F K Knop, J P Thyssen, et al.
The Journal of Clinical Endocrinology and Metabolism|April 23, 2010
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjectsK B Hansen, T Vilsbøll, J I Bagger, et al.
Journal of Internal Medicine|July 16, 2015
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasisM Gyldenløve, T Vilsbøll, C Zachariae, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 21, 2016
Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control studyK H Mikkelsen, F K Knop, T Vilsbøll, et al.
Regulatory Peptides|June 25, 2010
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitisF K Knop, T Vilsbøll, S Larsen, et al.
Pageof 6